AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca trade and other receivables ($M) ($M)
Consolidated Statement of Financial Position (Postgres DB)
Latest, Q2 2026
14,330
Period ended Jun 30, 2026
Change on a year earlier
+1.1%
14,168 in Q2 2025
History
21 quarters
Since Q4 2015
Sources
18
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Trade and other receivables ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 14,330 | +1.1% | Form 6-K (filed 2026-07-27) ↗ |
| Q4 2025 | Dec 31, 2025 | 15,177 | +17.0% | Form 20-F (filed 2026-02-24) ↗ |
| Q2 2025 | Jun 30, 2025 | 14,168 | +28.3% | Form 6-K (filed 2025-07-29) ↗ |
| Q4 2024 | Dec 31, 2024 | 12,972 | +7.0% | Form 20-F (filed 2025-02-18) ↗ |
| Q2 2024 | Jun 30, 2024 | 11,047 | -0.4% | Form 6-K (filed 2024-07-25) ↗ |
| Q4 2023 | Dec 31, 2023 | 12,126 | +15.3% | Form 20-F (filed 2024-02-20) ↗ |
| Q2 2023 | Jun 30, 2023 | 11,092 | +24.5% | Form 6-K (filed 2023-07-28) ↗ |
| Q4 2022 | Dec 31, 2022 | 10,521 | +9.1% | Form 20-F (filed 2023-02-21) ↗ |
| Q2 2022 | Jun 30, 2022 | 8,908 | +40.2% | Form 6-K (filed 2022-07-29) ↗ |
| Q4 2021 | Dec 31, 2021 | 9,644 | +37.3% | Form 20-F (filed 2022-02-22) ↗ |
| Q2 2021 | Jun 30, 2021 | 6,356 | +26.5% | Form 6-K (filed 2021-07-30) ↗ |
| Q4 2020 | Dec 31, 2020 | 7,022 | +21.9% | Form 20-F (filed 2021-02-16) ↗ |
| Q2 2020 | Jun 30, 2020 | 5,024 | -5.5% | Form 6-K/A (filed 2020-07-31) ↗ |
| Q4 2019 | Dec 31, 2019 | 5,761 | +3.4% | Form 20-F (filed 2020-03-03) ↗ |
| Q2 2019 | Jun 30, 2019 | 5,319 | +1.2% | Form 6-K (filed 2019-07-25) ↗ |
| Q4 2018 | Dec 31, 2018 | 5,574 | +11.3% | Form 20-F (filed 2019-03-05) ↗ |
| Q2 2018 | Jun 30, 2018 | 5,257 | +20.9% | Form 6-K (filed 2018-07-26) ↗ |
| Q4 2017 | Dec 31, 2017 | 5,009 | +9.5% | Form 20-F (filed 2018-03-06) ↗ |
| Q2 2017 | Jun 30, 2017 | 4,348 | – | Form 6-K (filed 2018-07-26) ↗ |
| Q4 2016 | Dec 31, 2016 | 4,573 | -30.9% | Form 20-F (filed 2018-03-06) ↗ |
| Q4 2015 | Dec 31, 2015 | 6,622 | – | Form 20-F (filed 2018-03-06) ↗ |
Cite this data
StockData. (2026). AstraZeneca Trade and other receivables ($M) ($M), quarterly Q4 2015–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/fin_ar
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.